Madrigal Pharmaceuticals, INC Form 4 insider transactions

Madrigal Pharmaceuticals director Rebecca Taub exercised stock options and subsequently sold a significant number of shares, including a charitable contribution, under a pre-arranged trading plan.

Madrigal Pharmaceuticals' President and CEO, William John Sibold, earned 50,000 shares of common stock from performance-based units and subsequently sold 2,400 shares to cover tax obligations.

Mardi Dier, Madrigal Pharmaceuticals' EVP and CFO, exercised stock options and sold an equivalent number of shares under a Rule 10b5-1 trading plan.

Madrigal Pharmaceuticals' Chief Commercial Officer, Carole Huntsman, reported multiple sales of common stock on November 21, 2025, totaling 2,278 shares.

Madrigal Pharmaceuticals Director Richard S. Levy exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.

Kenneth Bate, a Director at Madrigal Pharmaceuticals, Inc., exercised stock options and subsequently sold a significant number of common shares on November 5, 2025.

Madrigal Pharmaceuticals CEO William John Sibold reported a planned sale of 7,279 shares of common stock at $445.63 per share to cover tax withholding obligations related to restricted stock unit vesting.

Madrigal Pharmaceuticals' President and CEO, William John Sibold, sold 7,616 shares of common stock for approximately $3.05 million through a pre-arranged 10b5-1 trading plan.

Baker Bros. Advisors and affiliated entities significantly increased their indirect beneficial ownership in Madrigal Pharmaceuticals, Inc. through multiple common stock purchases in August 2025.

Baker Bros. Advisors and related entities significantly increased their indirect beneficial ownership in Madrigal Pharmaceuticals common stock through multiple purchases.

Madrigal Pharmaceuticals' General Counsel, Shannon T. Kelley, sold 1,304 shares on August 18, 2025, primarily through a pre-arranged 10b5-1 trading plan and for tax obligations.

Director Kenneth Bate exercised stock options and sold shares of Madrigal Pharmaceuticals on August 15, 2025.

Madrigal Pharmaceuticals Director Paul A. Friedman exercised stock options and subsequently sold 129,172 shares of common stock under a pre-arranged 10b5-1 trading plan.

Madrigal Pharmaceuticals Director Paul A. Friedman exercised stock options and sold a significant number of shares in pre-planned transactions.

Madrigal Pharmaceuticals Director Rebecca Taub exercised stock options and sold over 46,000 shares for approximately $16.2 million under a pre-arranged trading plan.

Madrigal Pharmaceuticals director Daniel J. Brennan was granted 967 restricted stock units and options for 1,705 shares of common stock.

Madrigal Pharmaceuticals Director Rebecca Taub executed a planned transaction, exercising stock options and simultaneously selling an equal number of common shares.

A director at Madrigal Pharmaceuticals, Paul A. Friedman, exercised stock options and subsequently sold 1,400 shares of common stock for a significant profit, as part of a pre-arranged trading plan.

Paul A. Friedman, a Director at Madrigal Pharmaceuticals, exercised stock options and subsequently sold 28,876 shares of common stock for approximately $10.2 million under a Rule 10b5-1 trading plan.

A director at Madrigal Pharmaceuticals, Rebecca Taub, exercised stock options and subsequently sold shares totaling 29,101 shares over two days in July 2025, as part of a pre-scheduled Rule 10b5-1 trading plan.

Madrigal Pharmaceuticals, Inc. Director Kenneth Bate was granted 715 restricted stock units and 1,290 stock options on June 20, 2025, as part of his compensation package.

Madrigal Pharmaceuticals, Inc. Director Richard S. Levy was granted 715 restricted stock units and options to purchase 1,290 shares of common stock, vesting in 2026 subject to continued service.

Madrigal Pharmaceuticals, Inc. Director Jacqualyn A. Fouse was granted 203 restricted stock units and options to purchase 366 shares of common stock, aligning her interests with shareholders.

Julian C. Baker and Dr. Raymond Cheong, directors of Madrigal Pharmaceuticals, Inc., received grants of restricted stock units and non-qualified stock options as compensation, reported by Baker Bros. Advisors LP and its affiliated entities.

Madrigal Pharmaceuticals, Inc. director James M. Daly was granted 715 restricted stock units and 1,290 stock options on June 20, 2025, as part of his compensation.

Madrigal Pharmaceuticals, Inc. Director Paul A. Friedman reported the acquisition of restricted stock units and stock options as part of his compensation, aligning his interests with shareholders.

David Soergel, Chief Medical Officer of Madrigal Pharmaceuticals, reports the acquisition of restricted stock units and stock options.

Director Richard S. Levy exercised stock options and sold shares of Madrigal Pharmaceuticals on April 10, 2025.

Director Fred B. Craves reports multiple transactions involving Madrigal Pharmaceuticals stock, including acquisitions via option exercises and sales at prices ranging from approximately $322 to $335.

Mardi Dier, SVP and CFO of Madrigal Pharmaceuticals, sold 258 shares of common stock at a price of $323.04 per share on March 10, 2025, under a pre-arranged Rule 10b5-1 trading plan.